2020
Confidentiality Orders and Public Interest in Drug and Medical Device Litigation
Egilman AC, Kesselheim AS, Krumholz HM, Ross JS, Kim J, Kapczynski A. Confidentiality Orders and Public Interest in Drug and Medical Device Litigation. JAMA Internal Medicine 2020, 180: 292-299. PMID: 31657836, DOI: 10.1001/jamainternmed.2019.5161.Commentaries, Editorials and LettersMeSH KeywordsAccess to InformationConfidentialityDisclosureDrug IndustryHumansJurisprudenceLiability, LegalConceptsLegal practicePublic interestMedical device litigationImportant public health informationLegal standardsMedical device manufacturersLitigationSpecial communicationCourtObscure patternsCompany marketingMedical expertsRulesPublic health informationDevice manufacturersPublic healthSuccessful effortsLitigantsPracticePlaintiffsLawsuitsCertain typesInterestAccessDrug Administration
2016
The New Era of Informed Consent: Getting to a Reasonable-Patient Standard Through Shared Decision Making
Spatz ES, Krumholz HM, Moulton BW. The New Era of Informed Consent: Getting to a Reasonable-Patient Standard Through Shared Decision Making. JAMA 2016, 315: 2063. PMID: 27099970, PMCID: PMC5459384, DOI: 10.1001/jama.2016.3070.Peer-Reviewed Original Research
2013
Ushering in a New Era of Open Science Through Data Sharing: The Wall Must Come Down
Ross JS, Krumholz HM. Ushering in a New Era of Open Science Through Data Sharing: The Wall Must Come Down. JAMA 2013, 309: 1355-1356. PMID: 23508736, DOI: 10.1001/jama.2013.1299.Commentaries, Editorials and Letters
2011
Promoting transparency in pharmaceutical industry-sponsored research.
Ross JS, Gross CP, Krumholz HM. Promoting transparency in pharmaceutical industry-sponsored research. American Journal Of Public Health 2011, 102: 72-80. PMID: 22095335, PMCID: PMC3319748, DOI: 10.2105/ajph.2011.300187.Commentaries, Editorials and LettersConceptsClinical trial researchTrial researchIndividual clinical decisionsGuideline recommendationsEvidence-based practiceTRIAL REGISTRATIONSystematic reviewClinical decisionInvestigator contributionsTrial outcomesMedical literaturePublic healthSelective publicationClinical trial data analysisHealthTrial data analysisIndustry-sponsored researchPatientsPhysiciansA Model for Dissemination and Independent Analysis of Industry Data
Krumholz HM, Ross JS. A Model for Dissemination and Independent Analysis of Industry Data. JAMA 2011, 306: 1593-1594. PMID: 21990302, PMCID: PMC3688082, DOI: 10.1001/jama.2011.1459.Commentaries, Editorials and Letters
2010
Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–4
Ross JS, Krumholz HM. Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications–4. Mayo Clinic Proceedings 2010, 85: 199-200. PMID: 20118400, PMCID: PMC2813835, DOI: 10.4065/mcp.2009.0744.Commentaries, Editorials and Letters
2009
Relationships with the drug industry: More regulation, greater transparency
Krumholz HM, Ross JS. Relationships with the drug industry: More regulation, greater transparency. The BMJ 2009, 338: b211. PMID: 19193612, DOI: 10.1136/bmj.b211.Commentaries, Editorials and Letters
2008
Updated Estimates of Pharmaceutical Company Payments to Physicians in Vermont
Ross JS, Nazem AG, Lurie P, Lackner JE, Krumholz HM. Updated Estimates of Pharmaceutical Company Payments to Physicians in Vermont. JAMA 2008, 300: 1998-2000. PMID: 18984886, DOI: 10.1001/jama.2008.560.Peer-Reviewed Original ResearchThe ADVANTAGE seeding trial: a review of internal documents.
Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals Of Internal Medicine 2008, 149: 251-8. PMID: 18711155, DOI: 10.7326/0003-4819-149-4-200808190-00006.Peer-Reviewed Original ResearchGuest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation
Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest Authorship and Ghostwriting in Publications Related to Rofecoxib: A Case Study of Industry Documents From Rofecoxib Litigation. JAMA 2008, 299: 1800-1812. PMID: 18413874, DOI: 10.1001/jama.299.15.1800.Peer-Reviewed Original Research
2007
Ischaemic symptoms, quality of care and mortality during myocardial infarction
Schelbert EB, Rumsfeld JS, Krumholz HM, Canto JG, Magid DJ, Masoudi FA, Reid KJ, Spertus JA. Ischaemic symptoms, quality of care and mortality during myocardial infarction. Heart 2007, 94: e2. PMID: 17639097, PMCID: PMC3703470, DOI: 10.1136/hrt.2006.111674.Peer-Reviewed Original ResearchConceptsIschemic symptomsMyocardial infarctionQuality of careST-elevation myocardial infarctionACE/ARBNon-cardiac comorbiditiesPositive cardiac enzymesEvidence of infarctionHospital mortalityCessation counsellingHospital survivalReperfusion therapyCardiac enzymesConsecutive patientsMI careMI symptomsCare indicatorsPatient reportsSymptom recognitionChart documentationPatientsUS hospitalsSymptomsInfarctionCarePharmaceutical Company Payments to Physicians: Early Experiences With Disclosure Laws in Vermont and Minnesota
Ross JS, Lackner JE, Lurie P, Gross CP, Wolfe S, Krumholz HM. Pharmaceutical Company Payments to Physicians: Early Experiences With Disclosure Laws in Vermont and Minnesota. JAMA 2007, 297: 1216-1223. PMID: 17374816, DOI: 10.1001/jama.297.11.1216.Peer-Reviewed Original ResearchImpact of the Food and Drug Administration’s Public Health Notification on the Adoption of Drug-Eluting Stents
Curtis JP, Cohen DJ, Jones PG, Bach RG, Spertus JA, Krumholz HM. Impact of the Food and Drug Administration’s Public Health Notification on the Adoption of Drug-Eluting Stents. The American Journal Of Cardiology 2007, 99: 1227-1229. PMID: 17478147, DOI: 10.1016/j.amjcard.2006.12.031.Peer-Reviewed Original ResearchConceptsPublic health notificationDrug-eluting stentsDES useDrug Administration Public Health NotificationsUse of DESDrug Administration NotificationProspective registryMyocardial infarctionDES safetyClinical practiceStudy periodStentsRelative decreaseTemporary effectInfarctionPatientsNotificationFoodRegistryDramatic increaseMeasuring Performance For Treating Heart Attacks And Heart Failure: The Case For Outcomes Measurement
Krumholz HM, Normand SL, Spertus JA, Shahian DM, Bradley EH. Measuring Performance For Treating Heart Attacks And Heart Failure: The Case For Outcomes Measurement. Health Affairs 2007, 26: 75-85. PMID: 17211016, DOI: 10.1377/hlthaff.26.1.75.Peer-Reviewed Original Research
2004
Management of implantable cardioverter defibrillators in end-of-life care.
Goldstein NE, Lampert R, Bradley E, Lynn J, Krumholz HM. Management of implantable cardioverter defibrillators in end-of-life care. Annals Of Internal Medicine 2004, 141: 835-8. PMID: 15583224, DOI: 10.7326/0003-4819-141-11-200412070-00006.Peer-Reviewed Original Research
2003
Disclosure of financial competing interests in randomised controlled trials: cross sectional review
Gross CP, Gupta AR, Krumholz HM. Disclosure of financial competing interests in randomised controlled trials: cross sectional review. The BMJ 2003, 326: 526. PMID: 12623910, PMCID: PMC150461, DOI: 10.1136/bmj.326.7388.526.Peer-Reviewed Original Research